Evidence map›Paper›PMID 27815175›Full record

ArticleThe Journal of investigative dermatology2017

Polyomavirus-Negative Merkel Cell Carcinoma: A More Aggressive Subtype Based on Analysis of 282 Cases Using Multimodal Tumor Virus Detection.

Ata S Moshiri, Ryan Doumani, Lola Yelistratova, Astrid Blom, Kristina Lachance, Michi M Shinohara, Martha Delaney, Oliver Chang, Susan McArdle, Hannah Thomas and 4 more

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of investigative dermatology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 119 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
119citing papers in PubMed, 2 pooled it
13.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

119 citing papers in PubMed, 2 syntheses or guidelines pooled it, 271 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020
    Trial
  7. The Role of Anti-PD-1/PD-L1 in the Treatment of Skin Cancer.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2020
    Trial
  8. Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2019
    Trial
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

59 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Ata S MoshiriDivision of Dermatology, Department of Medicine, University of Washington, Seattle, Washington, USA.
Ryan DoumaniDivision of Dermatology, Department of Medicine, University of Washington, Seattle, Washington, USA.
Lola YelistratovaDivision of Dermatology, Department of Medicine, University of Washington, Seattle, Washington, USA.
Astrid BlomDivision of Dermatology, Department of Medicine, University of Washington, Seattle, Washington, USA.
Kristina LachanceDivision of Dermatology, Department of Medicine, University of Washington, Seattle, Washington, USA.
Michi M ShinoharaDivision of Dermatology, Department of Medicine, University of Washington, Seattle, Washington, USA; Division of Dermatopathology, Department of Pathology, University of Washington, Seattle, Washington, USA.
Martha DelaneyDivision of Dermatopathology, Department of Pathology, University of Washington, Seattle, Washington, USA; Department of Comparative Medicine, University of Washington, Seattle, Washington, USA.
Oliver ChangDivision of Dermatopathology, Department of Pathology, University of Washington, Seattle, Washington, USA.
Susan McArdleDepartment of Laboratory Medicine, University of Washington, Seattle, Washington, USA.
Hannah ThomasDivision of Dermatology, Department of Medicine, University of Washington, Seattle, Washington, USA.
Maryam M AsgariDepartment of Dermatology, Massachusetts General Hospital, Boston, Massachusetts, USA.
Meei-Li HuangDepartment of Laboratory Medicine, University of Washington, Seattle, Washington, USA.
Stephen M SchwartzFred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Paul NghiemDivision of Dermatology, Department of Medicine, University of Washington, Seattle, Washington, USA; Fred Hutchinson Cancer Research Center, Seattle, Washington, USA. Electronic address: pnghiem@uw.edu.
University of Washington · USFred Hutch Cancer Center · USMassachusetts General Hospital · US

Funding

Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Marian Esvelt · 1985 to 2026
$296.4M
NRSA Training CoreTL1TR002318 · NCATS · UNIVERSITY OF WASHINGTON · PI Megan Moore · 2017 to 2026
$8.4M
Viral oncoprotein targeted immune therapy for Merkel cell carcinomaR01CA176841 · NCI · UNIVERSITY OF WASHINGTON · PI NGHIEM, PAUL · 2013 to 2016
$2.6M
Institute of Translational Health SciencesTL1TR000422 · NCATS · UNIVERSITY OF WASHINGTON · PI DISIS, MARY L. · 2012 to 2016
$2.1M
Pathogenetic and prognostic studies for improved therapy of Merkel cell carcinomaK24CA139052 · NCI · UNIVERSITY OF WASHINGTON · PI NGHIEM, PAUL · 2009 to 2018
$1.8M
Humoral and cellular immunity in polyomavirus-linked Merkel cell carcinomaR01CA162522 · NCI · UNIVERSITY OF WASHINGTON · PI NGHIEM, PAUL · 2011 to 2015
$1.6M
NCATS NIH HHS TL1 TR000422NCATS NIH HHS TL1 TR002318NCI NIH HHS K24 CA139052NCI NIH HHS P30 CA015704NCI NIH HHS R01 CA162522NCI NIH HHS R01 CA176841
6 · The paper itself

Abstract

Previous studies have reached conflicting conclusions regarding the proportion of Merkel cell carcinomas (MCCs) that contain the Merkel cell polyomavirus (MCPyV) and the clinical significance of tumor viral status. To address these controversies, we detected MCPyV large T antigen using immunohistochemistry with two distinct antibodies and MCPyV DNA using quantitative PCR. Tumors were called MCPyV-positive if two or more of these three assays indicated presence of this virus. A total of 53 of 282 (19%) MCC tumors in this cohort were virus-negative using this multimodal system. Immunohistochemistry with the CM2B4 antibody had the best overall performance (sensitivity = 0.882, specificity = 0.943) compared with the multimodal classification. Multivariate analysis including age, sex, and immunosuppression showed that, relative to MCC patients with virus-positive tumors, virus-negative MCC patients had significantly increased risk of disease progression (hazard ratio = 1.77, 95% confidence interval = 1.20-2.62) and death from MCC (hazard ratio = 1.85, 95% confidence interval = 1.19-2.89). We confirm that approximately 20% of MCCs are not driven by MCPyV and that such virus-negative MCCs, which can be quite reliably identified by immunohistochemistry using the CM2B4 antibody alone, represent a more aggressive subtype that warrants closer clinical follow-up.

Indexed as

AgedBiopsy, NeedleCarcinoma, Merkel CellCohort StudiesConfidence IntervalsDisease ProgressionFemaleHumansImmunohistochemistryMaleMerkel cell polyomavirusMiddle AgedMultivariate AnalysisNeoplasm InvasivenessNeoplasm StagingPrognosis

Identifiers

PMID27815175
PMCPMC5565758
OpenAlexW2547701444

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.